CERVAVAC® Vaccine Information

Cervavac 1 dose mono carton

CERVAVAC® stands as India’s pioneering HPV vaccine, cultivated domestically to prevent cervical cancer. This quadrivalent vaccine combats four distinct HPV variants (HPV 6, 11, 16, and 18).

  • Pune’s Serum Institute of India (SII) developed the initial Indian cervical cancer vaccine, also known as the human papillomavirus (HPV) vaccine (qHPV).
  • The Drugs Controller General of India (DGCI) granted approval for its use.
  • This vaccine resulted from collaborative efforts between SII and the Department of Biotechnology (DBT).

Vaccine Composition Information

Each dose of 0.5 ml contains:

Human Papillomavirus type 6 L1 protein ≥ 20 mcg

Human Papillomavirus type 11 L1 protein ≥ 40 mcg

Cervavac composition information

Human Papillomavirus type 16 L1 protein ≥ 40 mcg

Human Papillomavirus type 18 L1 protein ≥ 20 mcg

Al+++ ≤ 1.25 mg

Dosage Info

For vaccine recipients between 9 and 14 years old, CERVAVAC® should be administered according to a 2-dose schedule (0.5 ml at 0 and 6 months).

For vaccine recipients between 15 and 26 years old, CERVAVAC® should be administered according to a 3-dose schedule (0.5 ml at 0, 2, and 6 months).

Vaccine dose for 15 to 26 years olds

The second dose should be administered at least one month after the first dose and the third dose should be administered at least 3 months after the second dose. All three doses should be given within a 1-year period.